4D Molecular Therapeutics has reported positive safety data from the Phase I dose escalation clinical trial of its rare eye disease drug candidate, 4D-110, to treat choroideremia.
Initial safety results of the drug candidate’s two dose levels showed favourable tolerability without any dose-limiting toxicity.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
However, 4D Molecular partner Roche has decided to terminate their collaboration and licence agreement covering 4D-110. The termination is effective as of 16 September 2021.
Roche also requested the conclusion of the 4D-110 trial for advanced choroideremia based on its review of a change in the risk-benefit profile.
This move will return full 4D-110 rights to 4D Molecular, which intends to continue the development of the drug candidate.
4D Molecular plans to submit the safety and efficacy findings from the completed Phase I trial and a new study protocol to the US Food and Drug Administration soon.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataWith enrolment already complete, the Roche-funded 4D-110 trial will be concluded, and previously treated patients will be moved to a 4D Molecular-sponsored long-term follow-up study.
4D Molecular Therapeutics Clinical Research senior vice-president and Clinical Ophthalmology head Robert Kim said: “We plan to conclude the Roche-funded clinical trial under the collaboration and subsequently transfer previously treated patients onto a long-term follow-up study to continue monitoring biological activity endpoints and safety.
“We are committed to designing and initiating the next 4D-110 clinical trial, including treatment of earlier-stage patients, as soon as possible after reviewing the clinical data with our investigators and the FDA.”
The company also reported that its other rare disease ophthalmology candidate, 4D-125, was well-tolerated and did not cause any dose-limiting toxicity, according to initial safety findings in the Phase I part of a Phase I/II trial in X-linked retinitis pigmentosa (XLRP) patients.
Initial biologic activity data of both 4D-110 and 4D-125 are set to be available in the fourth quarter of this year.
